973 F.3d 22
1st Cir.2020Background
- ReWalk Robotics marketed a post-market exoskeleton (ReWalk Personal) that the FDA classified as Class II and ordered a Section 522 postmarket surveillance study to assess falls and related injuries.
- ReWalk’s August 2014 IPO Registration Statement disclosed the FDA-ordered study and general safety risks but did not explicitly state the FDA’s phrasing about a reasonable likelihood of serious injury from falls. ReWalk raised ~$41 million; Yan bought shares on Sept. 15 and 17, 2014.
- ReWalk and the FDA engaged in repeated exchanges; FDA deemed several study plans inadequate and issued a September 30, 2015 warning letter stating the device was "misbranded" absent correction. ReWalk did not disclose that letter to investors until late February 2016, after which the stock dropped ~13%.
- Plaintiffs filed a class action initially under the Securities Act; later amended to add Exchange Act (§10(b)/Rule 10b-5) claims based on post-IPO alleged omissions. District court dismissed the Securities Act claims and held Yan lacked standing to pursue the Exchange Act claims.
- Yan sought leave to amend to add Joanne Geller as a class representative for the Exchange Act claims. The district court denied leave, reasoning Yan lacked standing to seek such amendment. On appeal, the First Circuit affirmed dismissal of the Securities Act claims, rejected the district court’s standing-based bar to amendment but affirmed denial of the amendment as futile because the amended complaint failed to state an Exchange Act claim.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the IPO Registration Statement violated Section 11 / contained actionable omissions (including under Reg S-K) | Yan: Registration Statement was misleading because it omitted that FDA found device failures reasonably likely to cause serious injury/death and omitted risks of non-institutional use | ReWalk: Registration Statement disclosed the FDA-ordered study, warned of serious injury risk and limited long-term data; statements were truthful or puffery; Reg S-K not invoked in complaint | Held: Statements were not misleading; puffery protection applied; Reg S-K theory fails because the Registration Statement adequately disclosed the claimed risks — Securities Act claims dismissed |
| Whether challenged forward-looking statements are protected by the statutory safe harbor | Yan: District court improperly relied sua sponte on safe-harbor to dismiss statements | ReWalk: Statements are forward-looking and accompanied by meaningful cautionary language and thus nonactionable | Held: Safe-harbor applies; forward-looking statements were accompanied by cautionary risk factors and are nonactionable |
| Whether Yan has Article III standing to pursue Exchange Act claims based on post-IPO omissions or to represent purchasers who bought post-IPO | Yan: Alleged a common scheme tying IPO statements to later omissions, so early purchasers can represent the class; alternatively, allow substitution of a later purchaser as lead plaintiff | ReWalk: Post-IPO omissions occurred after Yan’s purchases; Yan therefore lacks standing for Exchange Act claims | Held: No plausible common-scheme tying misleading IPO statements to later fraud; post-IPO alleged omissions arose after Yan’s purchases, so Yan lacks standing to prosecute Exchange Act claims he personally did not suffer |
| Whether district court erred in denying leave to amend to add Geller as class representative | Yan: Even if he lacks standing for Exchange Act claims, the court may permit amendment/substitution to add a plaintiff who has standing | ReWalk: If original plaintiff lacked standing, court may deny substitution; amendment unnecessary or futile | Held: District court erred to the extent it invoked Yan’s lack of standing as per se bar to amendment; however, amendment to add Geller would be futile because the amended complaint fails to plead an actionable Exchange Act claim (no strong inference of scienter and no duty to disclose routine FDA back-and-forth) |
Key Cases Cited
- Omnicare Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (opinion on when omissions render opinions/statement misleading)
- Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308 (standard for evaluating whether allegations create a "strong inference" of scienter)
- Silverstrand Invs. v. AMAG Pharm., Inc., 707 F.3d 95 (1st Cir.) (Section 11/Regulation S‑K pleading framework)
- Greebel v. FTP Software, Inc., 194 F.3d 185 (1st Cir.) (puffery and optimistic statements not actionable)
- Sierra Club v. Morton, 405 U.S. 727 (Sup. Ct.) (standing principles; leave to amend to cure standing defects noted)
- Adams v. Watson, 10 F.3d 915 (1st Cir.) (permitting amendment to cure standing defects)
- Advanced Magnetics, Inc. v. Bayfront Partners, Inc., 106 F.3d 11 (2d Cir.) (denial of substitution should be reviewed for futility; Rule 15 permissive)
- Kader v. Sarepta Therapeutics, Inc., 887 F.3d 48 (1st Cir.) (limits on duty to disclose intermittent regulatory communications)
- Miss. Pub. Emps.' Ret. Sys. v. Bos. Sci. Corp., 649 F.3d 5 (1st Cir.) (scienter by recklessness standard and inference analysis)
- Pruell v. Caritas Christi, 645 F.3d 81 (1st Cir.) (jurisdictional analysis limited to named plaintiffs; does not bar amendment to add plaintiffs)